MEDICAMEN BIOTECH CMP 516A long Weekly trendline breakout Looks amazing in charts
If sustaining above 530, New Target will be 626/727
Its a definitely a portfolio stock to be kept in holdings for double
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
6.65 INR
109.31 M INR
1.79 B INR
5.17 M
About MEDICAMEN BIOTECH LTD
Sector
Industry
CEO
Rajesh Madan
Website
Headquarters
New Delhi
Founded
1993
ISIN
INE646B01010
FIGI
BBG000FNT910
Medicamen Biotech Ltd. engages in the manufacture and marketing of pharmaceutical formulations. Its products include tablets, capsules, liquid syrup, dry syrup, ointment, and ORS. Its products include cancer care, cardiology, CNS, diabetology, other generics, and pain management. The company was founded by Bal Kishan Gupta on December 22, 1993 and is headquartered in New Delhi, India.
Medicamen Biotech LtdMedicamen Biotech Ltd
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations.
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an inte
LONGW pattern , Double bottom pattern, its reversed after a long down trend. Likely targets given, strictly for long term.
risky trade in medicameqEmerging Tendulkar. Giving very good risk to reward. First target around 15%. Second 35%. Third 70%
Volatily contractionVolume dry-up; drifting sideways around 21 EMA.
Inside day candles.
RS higher; moved +6% where nifty tumbled by -2%.
EPS score of 91
RS rating 50
Pivot bought at 860.
SL 802
Publishing for my own reference. Not an investment/trading advise.
Medicamen Biotech------------ Long PlanMedicamen Biotech Ltd develops and markets a wide range of branded and generic formulations in the pharmaceutical industry.
KEY POINTS
Product Offerings
The company manufactures a wide range of formulations in the form of tablets, capsules, liquid syrup, dry syrup (beta lactum & non-beta lactum)
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of MEDICAMEQ is 473.80 INR — it has decreased by −2.60% in the past 24 hours. Watch MEDICAMEN BIOTECH LTD stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange MEDICAMEN BIOTECH LTD stocks are traded under the ticker MEDICAMEQ.
MEDICAMEQ stock has fallen by −3.28% compared to the previous week, the month change is a 13.65% rise, over the last year MEDICAMEN BIOTECH LTD has showed a 13.51% increase.
MEDICAMEQ reached its all-time high on Sep 1, 2022 with the price of 1,225.00 INR, and its all-time low was 355.45 INR and was reached on Mar 13, 2024. View more price dynamics on MEDICAMEQ chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MEDICAMEQ stock is 6.11% volatile and has beta coefficient of 2.14. Track MEDICAMEN BIOTECH LTD stock price on the chart and check out the list of the most volatile stocks — is MEDICAMEN BIOTECH LTD there?
Today MEDICAMEN BIOTECH LTD has the market capitalization of 6.17 B, it has increased by 0.23% over the last week.
Yes, you can track MEDICAMEN BIOTECH LTD financials in yearly and quarterly reports right on TradingView.
MEDICAMEN BIOTECH LTD is going to release the next earnings report on May 28, 2025. Keep track of upcoming events with our Earnings Calendar.
MEDICAMEQ net income for the last quarter is 34.74 M INR, while the quarter before that showed 14.56 M INR of net income which accounts for 138.57% change. Track more MEDICAMEN BIOTECH LTD financial stats to get the full picture.
Yes, MEDICAMEQ dividends are paid annually. The last dividend per share was 1.00 INR. As of today, Dividend Yield (TTM)% is 0.21%. Tracking MEDICAMEN BIOTECH LTD dividends might help you take more informed decisions.
MEDICAMEN BIOTECH LTD dividend yield was 0.26% in 2023, and payout ratio reached 11.58%. The year before the numbers were 0.15% and 8.39% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 17, 2025, the company has 378 employees. See our rating of the largest employees — is MEDICAMEN BIOTECH LTD on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDICAMEN BIOTECH LTD EBITDA is 212.17 M INR, and current EBITDA margin is 13.82%. See more stats in MEDICAMEN BIOTECH LTD financial statements.
Like other stocks, MEDICAMEQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDICAMEN BIOTECH LTD stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDICAMEN BIOTECH LTD technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDICAMEN BIOTECH LTD stock shows the sell signal. See more of MEDICAMEN BIOTECH LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.